Press releases & Ad hoc News

VERAXA Biotech Receives 99.57% Approval for Merger - Path to NASDAQ Listing Under «VRXA» Cleared

Update on Ongoing Transactions with Pharmaceutical Company Grupo Landsteiner and the NASDAQ Listing of VERAXA Biotech AG

Xlife Sciences AG Announces Transition to the Main Segment of SIX Swiss Exchange to Strengthen Market Presence

Award-Winning Liver PET Tracer Highlights the Strength of Our Innovation Portfolio

Xlife Sciences AG Provides Update on VERAXA Biotech AG’s NASDAQ Listing Process Following U.S. Government Shutdown

Xlife Sciences AG Publishes 2024 ESG Report: Sustainable Value Creation as a Strategic Core

Xlife Sciences AG’s Portfolio Company, VERAXA Biotech AG, Takes Key Step Toward NASDAQ Listing with Filing of Form F-4

Xlife Sciences AG: Successful General Meeting and Growth Prospects for 2025

Strategic Collaboration Between Xlife Sciences AG, Huraypositive Corp., and OncoMASTER Inc. to Boost Digital Health and Precision Oncology in Asia

Strategic Alliance Between Xlife Sciences AG, JIPYONG LLC and JIPYONG IP to Accelerate Korean Life Sciences Ventures’ Access to Global Capital Markets

Xlife Sciences AG Announces Strategic Collaboration between Portfolio Company Firstgene Life Sciences and Hovione in the Field of Gene Therapy

Xlife Sciences AG Publishes 2023 ESG Report: A Continued Commitment to Sustainable Innovation

Xlife Sciences AG: Successful General Assembly and New Trading Hours on the Sparks Segment of SIX

Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness

Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH

Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland

Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City

Xlife Sciences AG Achieves Significant Milestone in the Development of Radiodiagnostics for Liver Diseases

Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases

ESG Report shows status quo and outlines path for future sustainability improvements

Shareholders approved all motions at today’s AGM 2023

Stifel initiates research coverage of Xlife Sciences

Xlife Sciences: Swiss portfolio company Axenoll receives strategically significant patent by the European Patent Office

Xlife Sciences portfolio company launches project to research a potential therapy for amyotrophic lateral sclerosis (ALS)

Portfolio company Lysatpharma and joint venture Novaxomx start with research and product development in biosurgical treatment therapies

alytas therapeutics collaborates with spin-off from the German Diabetes Center

ProcCluster® from portfolio company inflamed pharma granted US patent

Laxxon Medical achieves major milestone

Xlife Sciences strengthens sustainability activities with ESG strategy

Baader Bank initiates research coverage on Xlife Sciences

Intron Health commences research coverage of Xlife Sciences

FUSE-AI supports German pharmacies in digitization

Shareholders approve all agenda items for the Annual General Meeting 2022

Project company Xsight Optics successfully participates in start-up competition – prize money finances relevant R&D project

xprot, a project company of Xlife Sciences, signes cooperation agreement with the University of Mainz and the Thoraxklinik Heidelberg

Xlife Sciences and curasan form joint venture company to research biosurgical treatment therapies

Cooperation Xlife Sciences and Shenzhen Investment Holding Capital

Xlife Sciences raises CHF 5.0 million through capital increase

Xlife Sciences AG (XLS DE) appoints new Chief Financial Officer

Xlife Sciences AG (XLS DE): Successful license deal with Vitese Trading GmbH

Xlife Sciences AG (XLS DE): Collaboration with the University of Marburg

Xlife Sciences AG (XLS DE): curasan AG and Xlife Sciences AG cooperate in the field of regenerative medicine

Xlife Sciences AG (XLS): Portfolio project listed on the Stock Exchange

Xlife Sciences AG (XLS): Joint venture with Indivumed

Xlife Sciences AG (XLS): Joint venture with anfass Life Technologies

Xlife Sciences AG: Successful capital raising of six million Swiss francs

Xlife Sciences AG: Xlife Sciences expands its project portfolio

Xlife Sciences AG: M.M. Warburg sets price target to EUR 55.75

Research Publication

Xlife Sciences AG: New project company x-nuclear diagnostic GmbH acquires new proprietary technology in nuclear medical diagnostics

Xlife Sciences AG: Project company inflamed pharma GmbH obtains grant for COVID-19 project

Xlife Sciences AG: Xlife Sciences waives early redemption of the privately placed convertible bond until July 1, 2023

Xlife Sciences AG: Xlife Sciences shares traded on XETRA

Xlife Sciences AG: The project company FUSE-AI GmbH reaches another milestone by developing ProstateCarcinoma.ai

Press release: FUSE-AI GmbH and the University Hospital Jena develop cost-saving assistance system (German only)

Press Release: Xlife Sciences AG - New project in the portfolio

Press Release: Xlife Sciences AG - New project in the portfolio (German only)

Pressemitteilung: Velabs Therapeutics receives exclusive license from alytas therapeutics for the development of therapeutic antibodies as senolytics (German only)

Press Release: Xlife Sciences AG - New project in the portfolio (German only)

Press release: FUSE-AI, a project company of Xlife Sciences AG enters cooperation agreement with Aarau Cantonal Hospital

Press Release: Xlife Sciences AG - New project in the portfolio

Press Release: Xlife Sciences AG invests in Hamburg start-up (German only)

Press Release: Xlife Sciences AG - Listing at Munich stock exchange

Press Release: Xlife Sciences AG further expands the company’s Board of Directors

Press Release: Velabs Therapeutics enters into a screening cooperation with Chiome Bioscience in the field of GPCR-specific functional antibody screening after successful feasibility study

Press Release: Velabs Secures EUR 3,0 mio in Series B Financing

Press Release: Velabs and Chiome cooperate in GPCR-Specific Functional Antibody

Press Release: Velabs and BioMed X cooperate in Immunology

Press Release: Accelerating Antibody Discovery (German only)